WEDNESDAY, Oct. 28, 2020 — In November, Pfizer plans to ask the U.S. Food and Drug Administration for emergency authorization for its COVID-19 vaccine after safety milestones are achieved, CBS News reported Tuesday.
Pfizer said its final vaccine trial has enrolled almost all of the planned 44,000 participants worldwide. Nearly 36,000 had received the second shot of the vaccine as of Monday. The trial includes people as young as 12 years and those with chronic, stable HIV, hepatitis C, and hepatitis B, CBS News reported.
Pfizer expects to know soon if the vaccine is effective or not — Pfizer CEO Albert Bourla had said they expect to know if the vaccine works by the end of October.
The company has contracts with the United States, the European Union, and about 10 countries to deliver hundreds of millions of doses of the vaccine next year, assuming it is approved, CBS News reported.
CBS News Article
Source: Read Full Article